Can KRAS Positive Colorectal and Lung Cancer Finally be Targeted?

MedMaven

by Dr. C.H. Weaver M.D. 4/2020

The investigational KRAS G12C inhibitor drug Adagrasib (MRTX849) yielded clinical responses in patients with non-small cell lung cancer (NSCLC) and colorectal cancer, and other solid tumors harboring KRAS G12C mutations, according the results of a from the phase I - II Krystal clinical trials. (1,3,4)

RAS is an oncogene —a gene that encodes proteins that function as switches to turn on various genes for cell growth and division. Mutations in the RAS genes result in permanently “turned on” switches that in turn result in uninhibited cell division, which can lead to cancer. There are three types of RAS oncogenes, designated NRAS, GRAS, and KRAS. Although mutations in all three can cause cancer.

KRAS mutations are the most common oncogenic alteration in all of human cancers and there are currently no effective treatments available for patients with KRAS-mutant cancers. KRAS cancer driving mutation are present in 14% of NSCLC adenocarcinomas, 4% of colorectal cancers, 2% of pancreatic cancers as well as smaller percentages of several other difficult-to-treat cancers.

About Adagrasib (MRTX849)

Adagrasib is an investigational, orally available small molecule that is designed to potently and selectively inhibit a form of KRAS which harbors a substitution mutation (G12C). Adagrasib works by irreversibly and selectively binding to KRAS G12C in its inactive state, blocking its signaling to other cells and preventing cancer cell growth and proliferation; this leads to cancer cell death. Adagrasib is being evaluated in a phase 1/2 trial treating patients with molecularly identified, KRAS G12C-positive advanced solid tumors.

Among 51 NSCLC patients treated with adagrasib, 45% had an objective response, meaning that their cancers shrank by 30% or more and did not grow or spread to other parts of the body. The disease control rate was 96%, meaning that 49 out of the 51 patients showed a partial or complete response or had stable disease.

Out of 18 colorectal cancer patients three (17%) had a confirmed objective response and two of them continue to receive treatment. Disease control was seen in 17 of the patients (94%) and 12 of these patients continue to be treated.

Side effects included nausea (54%), diarrhea (51%), vomiting (35%), fatigue (32%) and increased levels of an enzyme that indicates minor liver irritation (20%). The only serious adverse side effect to occur in more than one patient was low sodium in the blood, which occurred

Over the last several years the clinical successes of genotype-directed therapy for patients with EGFR-mutated and ALK-rearranged lung cancers has been impressive. KRAS-mutant lung cancer however is much more common, and it finally appears as though researchers are zeroing in on its treatment with precision medicines. In addition to MRTX849 another medication in development, AMG510 also appears promising for targeting KRAS mutations. If the early findings with MRTX849 hold true doctors may finally have a treatment for this difficult to treat genetically driven cancer.

References:

  1. by phase I clinical trial presented today at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
  2. Govindan et al., Annals of Oncology, Volume 30, Issue Supplement_5, October 2019. ESMO 2019
  3. Abstract no: 3 LBA, “KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Advanced/Metastatic Non–Small-Cell Lung Cancer (NSCLC) Harboring KRAS G12C Mutation”, by Pasi Jänne, presented in the Late Breaking and Best Proffered Papers Plenary session 2, channel 1, 15.45 hrs CET on Sunday 25 October:
  4. Abstract no: 4 LBA, “KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Patients with Colorectal Cancer (CRC) and Other Solid Tumors Harboring a KRAS G12C Mutation”, by Melissa Johnson, presented in the Targeting Oncogenic RAS signalling: New Approaches To An Old Problem scientific session, Channel 2, 19.30 hrs CET on Sunday 25
Comments

Colon

FEATURED
COMMUNITY